Full-length tissue factor pathway inhibitor (TFPI) is assumed to be biologically more important than truncated TFPI because of its stronger anticoagulant effect in the diluted prothrombin time (dPT) assay. We have developed a dPT-based assay for TFPI anticoagulant activity. Here, we report the effect of hormonal state on TFPI anticoagulant activity and whether TFPI anticoagulant activity assesses the risk for deep-vein thrombosis (DVT) better than conventional TFPI assays. We undertook a case-control study of 474 patients with DVT and 474 controls and compared the odds ratio (OR) for DVT for those with low TFPI anticoagulant activity with the ORs obtained for TFPI free and total antigen, and TFPI chromogenic substrate activity. Hormonal state affected clot time in dPT, but this effect was ameliorated by anti-TFPI antibodies. Low TFPI anticoagulant activity gave an OR of 1AE5 (0AE97-2AE1) for DVT, similar to the ORs obtained with conventional TFPI assays, ranging from 1AE2 to 1AE4. Individuals low in both the activity assays obtained an OR of 5AE9 (1AE7-20). We concluded that the effect of hormonal state on dPT was mediated through TFPI, and a dPT-based assay of TFPI anticoagulant activity did not assess the risk for DVT better than conventional TFPI assays.
Tissue factor pathway inhibitor 1 (TFPI) is the physiological inhibitor of blood coagulation initiated by tissue factor (TF). There is now convincing evidence that TFPI plays a key role in regulating blood coagulation in vivo. First, TFPI gene knockout mice suffered abnormal intrauterine development and death (Huang et al, 1997) . Secondly, immunodepletion of TFPI in rabbits significantly decreased the threshold by which TF may trigger coagulation and induce disseminated intravascular coagulation (Sandset et al, 1991a,b) . Thirdly, high doses of recombinant TFPI protected against various experimentally induced thrombotic disorders (Holst et al, 1993; Kaiser & Fareed, 1996; Bajaj & Bajaj, 1997) . Moreover, it has recently been reported that low levels of TFPI is a risk factor for both venous and arterial thrombosis (Dahm et al, 2003; Morange et al, 2004) . Therefore, it is intriguing that familial TFPI mutations associated with low levels of TFPI and increased risk of thrombosis have not yet been convincingly reported (Sandset & Bendz, 1997) .
In contrast to other coagulation inhibitors, e.g. antithrombin and protein C, the intravascular distribution of TFPI in vivo is rather complex. Most intravascular TFPI is free fulllength TFPI, which is associated with the vascular endothelium and which may be released by heparin and other negatively charged polyanions . A small amount of free full-length TFPI is also found in circulating blood, but plasma contains mostly truncated forms of TFPI, which is to a great extent, bound to lipoproteins (Novotny et al, 1989; Lindahl et al, 1991; Hansen et al, 1994) . The role of different forms of TFPI are not well known, but as full-length TFPI exerts a much stronger anticoagulant effect in diluted prothrombin time (dPT)-based assays than truncated and lipoprotein-associated TFPI (Lindahl et al, 1991; Nordfang et al, 1991; Hansen et al, 1995) , it has been suggested that fulllength TFPI is biologically more important in vivo. The complex distribution and functional aspects of TFPI raises the important question of how to detect TFPI deficiency and functional defects in vivo, and it has been speculated that a dPT-based assay of TFPI might reveal TFPI deficiencies that other assays fail to detect (Sandset & Bendz, 1997) . Currently published assays detect free full-length TFPI (TFPI-free antigen) or all forms of TFPI (TFPI total antigen) in plasma (Table I) . Functional assays involve prolonged incubation of TFPI in plasma with TF, factor VIIa (FVIIa) and factor Xa (FXa), which allows the formation of inactive TFPI/FXa/TF/FVIIa inhibitory complexes, and residual TF/ FVIIa catalytic activity is determined with a substrate, e.g. FX and a chromogenic substrate or tritium-labelled factor IX. Such functional assays correlated strongly with TFPI total antigen levels Dahm et al, 2005) and may be rather insensitive to functional defects of TFPI.
We have recently developed a novel assay of TFPI anticoagulant activity , which is based on the ability of TFPI to prolong the clotting time after initiation of coagulation with a low concentration of TF, i.e. a dPT assay. In this assay, dPT is run both in the presence and in the absence of TFPI neutralising antibodies. The shortening of clotting times in the presence of TFPI antibodies reflects TFPI anticoagulant activity. The TFPI anticoagulant activity assay is specific for full-length TFPI and insensitive to truncated TFPI. In the present study, we have evaluated the role of TFPI anticoagulant activity as a risk factor for the development of deep-vein thrombosis (DVT) and studied the effect of hormonal state on dPT and TFPI using blood samples collected in the Leiden Thrombophilia Study (LETS).
Patients and methods
Leiden thrombophilia study -study population and blood sampling
The design of the LETS case-control study has previously been described in detail (Koster et al, 1993) . Briefly, 474 patients with an objectively diagnosed first time DVT were compared with 474 sex-and age-matched controls. In a previous report, we reported TFPI free and total antigen and TFPI chromogenic substrate activity data in 473 patients and 473 control subjects (Dahm et al, 2003) . The current report concerns data on TFPI anticoagulant activity in 452 cases and 439 controls where blood samples were available for analysis. The patients were selected from three anticoagulation clinics in the Netherlands. The controls were acquaintances of the patients or partners of other patients. Patients with known malignancies were excluded and all patients were younger than 70 years of age. The Leiden University Medical Centre ethics committee approved the study protocol, and all participants gave informed consent according to the Declaration of Helsinki. Blood samples were taken between 6 and 56 months after the thrombosis was diagnosed, hence most patients had finished their anticoagulant treatment at the time of blood sampling. Whole blood (0AE9 v) was collected from the antecubital vein into Sarstedt Monovette tubes (Sarstedt, Nümbrecht, Germany) containing 0AE106 mol/l of trisodium citrate (0AE1 v). Plasma was prepared by centrifugation for 10 min at 2000 g at room temperature and stored in aliquots at )70°C until assayed.
TFPI assays
The 'TFPI anticoagulant activity' assay was based on the assay of dPT in the presence and the absence of neutralising TFPI antibodies (anti-TFPI IgG) as reported in detail elsewhere . Briefly, 32 ll of plasma was incubated with 8 ll Tris-buffered saline or 8 lL anti-TFPI IgG and incubated for 4-6 min at room temperature. Thirty microlitres of TF (Innovin4, diluted 1/200; Dade Behring, Marburg, Germany) was then added and incubated for 3 min at 37°C. Finally, 30 ll 35 mmol/l CaCl 2 was added and the time to clotting recorded with the Amelung KC4 coagulometer (Trinity Biotech, Bray, Ireland). Clotting time in the absence of anti-TFPI IgG was approximately 75 s, which was reduced by approximately 7-8 s in the presence of anti-TFPI IgG in normal reference plasma. Test results were expressed as a TFPI anticoagulant ratio of the dPT recorded in the absence of anti-TFPI IgG on the dPT in the presence anti-TFPI IgG. Both dPTs as well as the TFPI anticoagulant ratio were normalised against results obtained with the normal reference plasma to minimise the effects of variations in assay conditions, e.g. day-to-day and batch-to-batch variations or reagents. Thus, a low normalised dPT meant a short dPT, while a high normalised dPT meant a Because of the limited amounts of plasma, most blood samples were assayed in a single run. Interday coefficient of variation (CV) was 2AE8% and intraday CV was between 0AE5% and 1AE5%. The 'TFPI free antigen and TFPI total antigen' were assayed in duplicate with commercial enzyme-linked immunosorbent assays (ELISAs) (AsserachromÒ Free TFPI and AsserachromÒ Total TFPI; Diagnostica Stago, Asniére, France), described in detail elsewhere (Dahm et al, 2003) . Inter-and intra-assay variability, measured as CV was 4AE4% and 2AE9% for TFPI total antigen, and 4AE9% and 3AE8% for TFPI free antigen respectively. Bound TFPI was calculated as the difference between TFPI total antigen and TFPI-free antigen. The fraction of free, fulllength TFPI in plasma was calculated as the proportion of TFPI-free antigen in TFPI total antigen.
The 'TFPI chromogenic substrate activity' was assayed in duplicate with an inhouse two-stage chromogenic substrate assay, as described earlier . In this assay, TFPI activity was determined by the quantification of residual TF/FVIIa catalytic activity after the incubation of diluted plasma (containing TFPI) with TF, FVIIa in excess of TFbinding sites, and FXa. Inter-and intra-assay variability was 3AE5% and 1AE4% respectively.
Statistics
The controls represent the general population and were used to estimate the intravascular distribution of TFPI and to study the effect of hormonal state on dPT and the levels of TFPI.
To compare women using oral contraceptives (OC) with non-users, a special selection described earlier was made to obtain comparable groups (van Hylckama Vlieg et al, 2000) . Non-menopausal women between 15 and 49 years of age were included. Women, who at the index date (similar date as date of thrombosis for patients) were pregnant, within 30 days postpartum, had a recent miscarriage or had used only depot contraceptives were excluded. A total of 142 control subjects were included in this analysis. To compare women not using OC with postmenopausal women, the same selection was used except that one postmenopausal woman who had used depot contraceptives was excluded.
To study the role of different forms of TFPI we calculated the risk for thrombosis associated with low TFPI for the different TFPI parameters. OC decrease TFPI levels in blood (Dahm et al, 2003) . As OC is a well-known risk factor for DVT, many of the OC users with DVT stopped their use of OC at the time of diagnosis, and supposedly had higher TFPI at the time of blood sampling 6-56 months later. However, in the control group there was almost no change in OC use, hence OC users were omitted from the risk calculations (Dahm et al, 2003) . Individuals on oral anticoagulation were excluded because of their effect on dPT, three patients with extreme TFPI anticoagulant values were excluded .
In addition, a few individuals had missing residual blood samples available for analysis. Therefore, this study involves 362 patients and 363 controls, which is less than in our previous report (Dahm et al, 2003) . 'Low TFPI', for all TFPI parameters, was defined as TFPI below the 10th percentile among the controls as reported earlier (Dahm et al, 2003) . In the calculation of the odds ratio (OR) for DVT in those who were low in both TFPI anticoagulant activity and TFPI chromogenic substrate activity, 'low TFPI' was defined as those individuals with TFPI below the 10th percentile in both assays at the same time, all others (i.e. those who had low TFPI in only one or none of the assays) were defined as having 'high TFPI'.
The TFPI values within groups of controls are reported as mean values and 95% confidence intervals (CI). Differences in mean values of normalised dPT between groups of controls with different hormonal state were tested with Student's t-test. P values below 0.05 were considered significant.
Results

Low TFPI anticoagulant activity as a risk factor for DVT
Normalised TFPI anticoagulant ratio below the 10th percentile gave an OR for DVT of 1AE5 (95% CI 0AE97-2AE4) (Table II) . To examine whether the TFPI anticoagulant activity assay assessed the risk for DVT differently from the other TFPI assays, ORs for DVT for TFPI levels below the 10th percentile were calculated in the same selection of cases and controls for TFPI free and total antigen, bound TFPI and TFPI chromogenic substrate activity. The ORs ranged from 1AE2 to 1AE4 (Table II) , i.e. the risk for DVT was quite similar in all TFPI assays and none of the assays proved more predictive in assessing the risk for DVT. ORs in hormonal subgroups (men, postmenopausal women and premenopausal women not using OC) were in the same range for all assays (data not shown).
Those individuals who had low TFPI in both the activity assays, i.e. low TFPI chromogenic substrate activity and low normalised TFPI anticoagulant ratio, had an OR of 5AE9 (1AE7-20), relative to those who were only low in one or low in neither assay (Table II) . Only three of the 363 (c. 1%) controls had low TFPI in both assays, in accordance with the expected prevalence based on the frequency of low values in each test of around 10%, which indicates that very few in the general population are affected by the risk for thrombosis due to low levels of TFPI in both activity assays. However, a separate study of the OC users in the healthy control group (who were excluded from other analyses, see Patients and methods) showed that 31 of 57 OC users (c. 54%) had low TFPI in both assays.
The effects of OC and hormonal state
Hormonal state had an explicit effect on the dPT. Premenopausal OC users had a shorter normalised dPT than non-users, and non-users had a shorter normalised dPT than postmenopausal women, who again had a shorter dPT than men. When TFPI was neutralised by anti-TFPI antibodies the difference in dPT between the hormonal subgroups were almost abolished, only some effect of male sex on dPT persisted (Table III) , which means that the effect of hormonal state on dPT was mainly mediated through the effect of hormonal state on plasma levels of TFPI. Hormonal state had a corresponding effect on the normalised TFPI anticoagulant ratio. OC users had the lowest ratios and postmenopausal women and men had highest ratios (Table IV) .
Estimation of the percentage-free TFPI of the total circulating TFPI in plasma
As the TFPI anticoagulant activity is a measure of the anticoagulant activity of the fraction of free full-length TFPI in plasma we investigated the effect of hormonal state on the fraction of free TFPI. The control group had a mean TFPI-free antigen/TFPI total antigen ratio of 0AE19 (standard deviation 0AE056, range 0AE070-0AE38). In other words, 19% of the total circulating TFPI was free full-length TFPI, but with large interindividual variation mainly due to hormonal state. In OC users, approximately 13% was free full-length TFPI, while fertile women not using OC had a mean of 18% free full-length TFPI. Postmenopausal women and men had approximately 20% of their TFPI in the free form (Table V) . Thus, it seems that hormonal state had a stronger effect on full-length than truncated TFPI in plasma.
Discussion
We and other investigators have previously hypothesised that full-length TFPI plays an important biological role in vivo because of its strong inhibitory effect in dPT-based assays (Lindahl et al, 1991; Nordfang et al, 1991; Hansen et al, 1995; Sandset & Bendz, 1997) . Hence, a dPT-based assay that can exclusively detect the functional activity of full-length TFPI might have the potential to detect TFPI deficiencies that other assays so far may have failed to detect (Sandset & Bendz, 1997; Ariens, 2005) . Our current data do not support this hypothesis. TFPI anticoagulant activity below the 10th percentile was associated with a mildly increased risk for DVT, which was similar to the risks associated with levels of TFPI below the 10th percentile detected in conventional TFPI assays.
We have recently shown that the plasma levels of TFPI-free antigen and TFPI anticoagulant activity are closely associated, and that the levels of TFPI chromogenic substrate activity and TFPI total antigen also are closely associated (Table I) . Therefore, it hardly seems necessary to use both the antigen assays and the activity assays in population-based studies. Measurements of TFPI free and total antigen will give a good impression of the TFPI anticoagulant activity and the TFPI chromogenic substrate activity, respectively, as well as of the risks for DVT associated with each assay. But in individuals with a suspected mutation, dual antigen and activity assay would be of interest to detect a dysfunctional protein.
The TFPI anticoagulant activity and TFPI chromogenic substrate activity are not very closely associated and do probably reflect different targets of inhibition in vivo . Based on this and other reports on the kinetics of the inhibition of FXa and TF/FVIIa by TFPI (Huang et al, 1993; Lindhout et al, 1994 Lindhout et al, , 1995 Lockett & Mast, 2002) , we suggest that the TFPI anticoagulant activity is a measure of the inhibition of FXa, while the TFPI chromogenic substrate activity is a measure of the inhibition of the TFPI/FXa complex (Table I) . TFPI anticoagulant activity and TFPI chromogenic substrate activity may therefore be considered to be independent risk factors for thrombosis. Moreover, both activity assays yielded approximately the same risk for DVT even though they were not closely associated [Table I and (Dahm et al, 2005) ]. We have tentatively calculated the risk for DVT for the Table III . Mean normalised diluted prothrombin time (dPT) with and without inhibiting anti-tissue factor pathway inhibitor (anti-TFPI) antibodies.
1AE02** 1AE12** 1AE16** 1AE20** N-dPT + anti-TFPI 1AE08 ns 1AE10 ns 1AE10 ns 1AE13* *P ¼ 0AE01; **P < 0AE01; ns, non-significant. Comparisons are between adjacent categories; OC, oral contraceptives.
individuals who had both low TFPI anticoagulant activity and low chromogenic substrate activity below the 10th percentile, and found that low levels were associated with an almost sixfold increase in the risk for DVT. The CI demonstrates the uncertainty of this risk estimate, and the usefulness of the combined measures warrants confirmation in other studies.
We also find it interesting that OC use was associated with the combination of low levels of TFPI anticoagulant activity and TFPI chromogenic substrate activity in >50% of users, when compared with <1% in the control subjects not using OC. These data further substantiate the potential important role that TFPI may play in increasing the risk of venous thrombosis in OC users.
Hormonal state had an effect on the normalised TFPI anticoagulant ratio comparable with that shown previously (Harris et al, 1999; Hoibraaten et al, 2001; Dahm et al, 2003) . Hormonal state, especially OC use, also affected the normalised dPT by shortening the clotting times. However, addition of anti-TFPI antibodies that completely ameliorated the effects of TFPI, resulted in nearly identical clotting times independent of hormonal state. Hence, the effects of OC and hormonal state on TF-initiated clotting time can, to a large extent, be attributed to the effects on full-length TFPI. This is supported by our recent finding that there was a clear relationship between the normalised dPT and plasma level of TFPI-free antigen, but not bound TFPI and anti-TFPI antibodies repressed this effect . This result also indicates that all assays triggered with TF, e.g. endogenous thrombin potential-based activated protein C resistance (de Visser et al, 2005) , are possibly affected by the level of fulllength TFPI in the sample assayed.
The fractions of free TFPI in plasma have been estimated by several authors using different methods (Novotny et al, 1989; Lindahl et al, 1991; Hansen et al, 1994) , and the results have varied from 3% to 20%. In the present study, the fraction of free full-length TFPI was approximately 20% using two different ELISAs with detecting monoclonal antibodies directed against either the first 160 amino acid residues of the TFPI molecule in the TFPI total antigen assay or against the last 161-240 residues in the TFPI-free antigen assay (Dahm et al, 2003) . We have recently confirmed in vivo that the full-length TFPI identified by the TFPI-free antigen assay had the same ability to inhibit coagulation as the fulllength TFPI investigated in vitro (Lindahl et al, 1991 (Lindahl et al, , 1992 Hansen et al, 1994 Hansen et al, , 1997 . Hence, we believe that we have made a fairly good estimate of the fraction full-length TFPI circulating in the blood. Hormonal state, especially OC use influenced the fraction of free TFPI profoundly, which suggests that hormonal state affects full-length TFPI in plasma more than truncated TFPI.
The assumption that full-length TFPI is biologically more important than truncated forms has been based on in vitro studies, and our study is the first to test this hypothesis in vivo. Our data suggest that full-length TFPI is not more important than truncated TFPI in vivo, but that both forms play a role in the protection against thrombosis. The increased risk related to the combined measure of the two activity assays suggest that the ability of TFPI to inhibit either FXa or TF/FVIIa, or both, still might be important for its anticoagulant effects in vivo. A more fundamental question is whether circulating TFPI actually plays any significant role in vivo. It could very well be that the most important pool of TFPI in vivo is the much larger pool of TFPI bound to the endothelium. The ORs observed for different plasma forms of TFPI could possibly be faint, and inaccurate, reflections of risks connected to the endothelium-associated TFPI, but this needs investigation in other studies. 
